Brain iron pathways and their relevance to Parkinson's disease

Journal of Neurochemistry

Volumn 79, Issue 2, 2001, Pages 225-236

  Berg, D ^a,e   Gerlach, M ^a,d   Youdim, M B H ^b,d   Double, K L ^a,c   Zecca, L ^a,d   Riederer, P ^a,d   Becker, G ^d,e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^d Center of Excellence for Parkinson's Disease of the National Foundation   (United States)

^e SAARLAND UNIVERSITY   (Germany)

Author keywords

synuclein aggregation; Auto oxidation; Iron metabolism; Oxidative stress; Parkinson's disease; Transcranial ultrasound

Indexed keywords

ALPHA SYNUCLEIN; CARRIER PROTEIN; CERULOPLASMIN; FERRITIN; HEME OXYGENASE; IRON; IRON REGULATORY FACTOR; LACTOFERRIN; NEUROMELANIN; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; TRANSFERRIN RECEPTOR;

DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DOPPLER ECHOGRAPHY; HUMAN; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; METABOLIC DISORDER; MICROGLIA; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; HOMEOSTASIS; HUMANS; IRON; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; PROTEIN PROCESSING, POST-TRANSLATIONAL; SYNUCLEINS;

EID: 0034776216     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00608.x     Document Type: Review

References (175)

1. A novel mammalian iron-regulated protein involved in intracellular iron metabolism
2. Iron dependent self-assembly of recombinant yeast frataxin. Implications for Friedreich Ataxia
3. Lactoferrin and transferrin: A comparative study
4. Iron metabolism
5. Glycosyl phosphatidylinositol membrane anchoring of melanotransferrin (p97): Apical compartmentalization in intestinal epithelial cells
6. Lactoferrin enhances hydroxyl radical production by human neutrophils, neutrophil particulate fractions, and an enzymatic generating system
7. Structure of human lactoferrin: Crystallographic structure analysis and refinement at 2.8A resolution
8. The iron transporter DMT1
9. T2 relaxation time in patients with Parkinson's disease
10. Structural and functional studies of human ferritin H and L chains
11. Iron and copper transport in yeast and its relevance to human disease
12. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism
13. Human melanotransferrin (p97) has only one functional iron-binding site
14. Studies of the slow bidirectional transport of iron and transferrin across the blood-brain barrier
15. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects
16. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography
17. Human ABC7 transporter, gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation
18. Iron-melanin interaction and lipid peroxidation: Implications for Parkinson's disease
19. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound
20. Iron accumulation of the substantia nigra in rats visualized by ultrasound
21. The basal ganglia in haemochromatosis
22. Substantia nigra hyper-echogenicity on transcranial ultrasound - State marker for Parkinson's disease and impact on disease course
23. Echo pattern of substantia nigra and its relevance for motor function and motility in elderly subjects
24. The interaction of lactoferrin with human monocytes
25. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease
26. The structure of neuromelanin and its iron binding site studied by infrared spectroscopy
27. Uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl radical and protects them from membrane autoperoxidation
28. Expression of genes for the ferritin H and L subunits in rat liver and heart
29. Effect of reactive oxygen species on iron regulatory protein activity
30. Deposition of iron in the paraventricular areas of the human brain in hemochromatosis
31. Iron regulation in the brain. Histochemical, biochemical and molecular considerations
32. Cellular distribution of transferrin, ferritin and iron in normal and aged human brains
33. Isoforms of ferritin have a specific cellular distribution in the brain
34. Iron absorption and transport
35. Selectivity of the Parkinson neurotoxin MPTP: Toxic metabolite MPP+ binds to neuromelanin
36. Fe-saturation and proteolysis of human lactoferrin: Effect on brush-border receptor mediated uptake of Fe and Mn
37. Clinical report of three patients with hereditary hemochromatosis and movement disorders
38. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia
39. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia
40. Increased nigral iron content and alterations in other metal ions occuring in brain in Parkinsons's disease
41. In vitro studies of ferritin iron release and neurotoxicity
42. Significance of neuromelanin for neurodegeneration in Parkinson's disease
43. Human ferritin gene expression
44. Nonidentical distribution of transferrin and ferric iron in human brain
45. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson's disease
46. 125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease
47. The hereditary hemochromatosis gene (HFE): A MHC class I-like gene that functions in the regulation of iron homeostasis
48. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding
49. Receptor-mediated transcytosis of lactoferrin through the blood - Brain barrier
50. Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment
51. Developmental regulation of hepatic ceruloplasmin mRNA and serum activity by exogenous thyroxine and dexamethasone
52. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: Increased duodenal expression of the iron transporter DMT1
53. Role of heme oxygenase-1 in the regulation of manganese superoxide dismutase gene expression in oxidatively-challenged astroglia
54. Overexpression of the ferritin iron-responsive element decreases the labile iron pool and abolishes the regulation of iron absorbtion by intestinal epithelial (Caco-2) cells
55. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
56. Altered brain metabolism of iron as a cause of neurodegenerative diseases
57. Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra
58. Iron in the Parkisonian substantia nigra
59. Anatomy, pigmentation, ventral and dorsal subpopulation of the substantia nigra, and differential cell death in Parkinson's disease
60. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease: A LAMMA study
61. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease
62. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy
63. Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation
64. The iron transport protein NRAMP2 is an integral membrane glycoprotein that colocalizes with transferrin in recycling endosomes
65. Cloning and characterisation of mammalian proton-coupled metal-ion transporter
66. Functional expression cloning and characterization of SFT, a stimulator of Fe transport
67. Characterization and chromosomal mapping of the human gene for SFT, a stimulator of Fe transport
68. Regulation of genes of iron metabolism by the iron-response proteins
69. The effect of age on non-haem iron in the human brain
70. Iron and free radical reactions: Two aspects of antioxidant protection
71. Regulation of the iron regulatory proteins by reactive nitrogen and oxygen species
72. Aceruloplasminemia. Molecular characterization of this disorder of iron metabolism
73. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux
74. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro
75. Studies on familial hypotransferrinemia: Unique clinical course and molecular pathology
76. Time-course and localisation of transferrin receptor expression in the substantia nigra of 6-hydroxydopamine-induced Parkinsonian rats
77. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress
78. The distribution of iron in the brain
79. Melanizd dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
80. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease
81. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin
82. Brain iron and ferritin in Parkinson's and Alzheimer's disease
83. Iron-melanin complex in substantia nigra of Parkinsonian brains: An x-ray microanalysis
84. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease
85. Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease
86. Ferritin immunohistochemistry as a marker for microglia
87. Iron metabolism in eukaryotes. Mars and Venus at it again
88. A novel iron uptake mechanism mediated by GPI-anchored human p97
89. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease
90. Effects of interferon-gamma and lipopolysaccharide on macrophage iron metabolism are mediated by nitric oxide-induced degradation or iron regulatory protein 2
91. Regulating the fate of mRNA: The control of cellular iron metabolism
92. Expression of the ceruloplamin gene in the human retina and brain: Implications for a pathogenetic model in aceruloplasminemia
93. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson' s disease
94. Preservation of midbrain catecholaminergic neurons in very old human subjects
95. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor
96. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease
97. Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not in Parkinson's disease
98. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders
99. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients
100. Lipoprotein in pigments - Their relationship to ageing in the human nervous system II. The melanin content of pigmented nerve cells
101. Possible role of neuromelanin in the pathogenesis of Parkinson's disease
102. Reduced expression of the G209A α-synuclein allele in familial parkinsonism
103. Regulation of iron metabolism: Translational effects mediated by iron, heme, and cytokines
104. Aging and extrapyramidal function
105. Aluminium enhances melanin-induced lipid peroxidation
106. Post-transcriptional control via iron-responsive elements, the impact of aberrations in hereditary disease
107. Hemochromatosis associated with brain lesions - A disorder of trace-metal binding proteins and/or polymers
108. Iron-melanin complex is toxic to dopaminergic neurons in a nigrostriatal co-culture
109. Apoptosis in neurodegenerative disorders
110. Iron-dependent neuronal expression of transferrin receptor mRNA in the rat
111. Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and beta2-microglobulin deficient mouse brain
112. Uptake and distribution of iron and transferrin in the adult rat brain
113. Transferrin receptors in the Parkinsonian midbrain
114. Proteolysis of human ceruloplasmin. Some peptide bonds are particular susceptible to proteolytic attack
115. Role of ceruloplasmin in cellular iron uptake
116. Crosslinking of α-synuclein by advanced glycation endproducts - An early pathophysiological step in Lewy body formation?
117. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India
118. Hereditary haemochromatosis, a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome
119. Transferrin stimulates iron absorbtion, exocytosis, and secretion in cultured intestinal cells
120. Tubular injury as a cardinal pathologic feature in human heme oxygenase-1 deficiency
121. Magnetic resonance imaging in parkinsonism
122. The A53T α-synuclein mutation increases iron dependent aggregation and toxicity
123. (II)-induced self oligomerization of α-synuclein
124. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method
125. Monocyte-macrophage ferric reductase activity is inhibited by iron and stimulated by cellular differentiation
126. The effect of melanin on iron associated decomposition of hydrogen peroxide
127. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
128. Cellular iron metabolism
129. The yeast frataxin homologue mediates mitochondrial iron efflux
130. Biochemical fundamentals of Parkinson's disease
131. Transition metals, ferritin, glutathione, and ascorbic acid in Parkisonian brains
132. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease
133. Differential localisation of divalent metal transporter 1 with and without iron response element in rat PC12 and sympathetic neuronal cells
134. Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium
135. Magnetic resonance imaging evidence of decreased putaminal iron content in idiopathic Parkinson's disease
136. Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin
137. Defective iron homeostasis in beta 2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man
138. Age-related hippocampal changes in Bcl-2. Bax ratio, oxidative stress, redox-active iron and apoptosis associated with aluminium-induced neurodegeneration: Increased susceptibility with aging
139. Astrocytes, brain aging and neurodegeneration
140. Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases
141. Expression of heme oxygenase-1 in senescent and Alzheimer-diseased brain
142. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease
143. Mitochondrial iron sequestration in dopamine-challenged astroglia. Role of heme oxygenase-1 in and the permeability transition pore
144. The iron content of the tissues in haemochromatosis, with special reference to the brain
145. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: An electron paramagnetic resonance spectroscopy study
146. Iron involvement in neural damage and microgliosis in models of neurodegerative disorders
147. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
148. Environmental agents and Parkinson's disease
149. α-synuclein in Lewy bodies
150. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disase and dementia with Lewy bodies
151. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles
152. Modulation by melanin of the availability and reactivity of metal ions
153. Human NRAMP2/DMT1, which mediates iron transport accross endosomal membranes, is localized to late endosomes and lysosomes in Hep-2 cells
154. Evidence for non-transferrin-mediated uptake and release of iron and manganese in glial cell cultures from hypotransferrinemic mice
155. Ferritin; structure, gene regulation, and cellular function in animals, plants and microorganisms
156. Targeting mRNA to regulate iron and oxygen metabolism
157. Copper, ceruloplasmin, superoxide dismutase and iron paramenters in Parkinson's disease
158. 59Fe uptake into the brain and cerebrospinal fluid and the influence there on antibodies against the transferrin receptor
159. A cellular stress model for the sequestration of redox-active glial iron in the aging and degenerating nervous system
160. Intranigral injected iron progressively reduces striatal dopamine metabolism
161. Intraneuronal aluminium potentiates iron-induced oxidative stress in cultured rat hippocampal neurons
162. Lactoferrin binding by leukemia cell lines
163. Basal ganglia iron content in Parkinson's disease measured with magnetic resonance
164. Activated microglia cause superoxide-mediated release of iron from ferritin
165. The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease
166. The enigma of neuromelanin in Parkinson's disease substantia nigra
167. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators
168. Ceruloplasmin, transferrin and apotransferrin facilitate iron release from human liver cells
169. Structural and functional analysis of SFF, a stimulator of Fe transport
170. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems
171. Total and paramagnetic metals in human substantia nigra and its neuromelanin
172. The chemical characterization of melanin contained in substantia nigra of human brain
173. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain
174. Interaction of neuromelanin and iron in the substantia nigra and other areas of human brain
175. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: Consequences for iron storage and neurodegenerative processes